<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878421</url>
  </required_header>
  <id_info>
    <org_study_id>2014CV10</org_study_id>
    <nct_id>NCT02878421</nct_id>
  </id_info>
  <brief_title>Vascular EffectS of regUlar Cigarettes Versus electronIc Cigarette USe</brief_title>
  <acronym>VESUVIUS</acronym>
  <official_title>Vascular Effects of Regular Cigarettes Versus electronIc Cigarette Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of electronic cigarettes-nicotine and
      electronic cigarette-nicotine free on endothelial function as compared to traditional
      cigarettes. Due to ethical reasons, we cannot fully randomise all particpants to the three
      arms.

      Participants who wish to quit smoking will be randomized to

        1. Switch to electronic cigarettes containing nicotine plus flavor

        2. Switch to electronic cigarettes containing flavor alone Those who do not wish to quit
           smoking will continue on the Tobacco Cigarette arm Treatment period will be 28 days
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electronic cigarettes (EC) are gaining popularity as an alternative to Traditional Cigarettes
      (TC). Despite not containing all the harmful substances seen in TC, EC are known to contain
      impurities that may have a detrimental impact on human health. The effects of ECs compared
      with TC on vascular function, inflammation and oxidative stress are unknown. It is
      increasingly recognised that nicotine itself has significant atherothrombotic effects.
      Therefore, clinicians are unable to confidently recommend ECs as a less risky alternative to
      TC.

      Hypothesis: Endothelial function will be improved on EC compared to TC when measured by flow
      mediated dilatation (FMD).

      Potential benefit: This study will provide further information on the potential use these
      devices and the risks and/or benefits associated with them, specifically in relation to
      vascular health.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2016</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow mediated Dilation (FMD) between the TC group and the EC-nicotine and EC-nicotine free groups</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FMD between EC-nicotine and EC-nicotine free groups</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FMD between TC and EC groups combined</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxidised LDL between the TC, EC-nicotine free and EC-nicotine groups</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PAI-1 between the TC, EC-nicotine free and EC-nicotine groups</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hs-CRP between the TC, EC-nicotine free and EC-nicotine groups</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Wave Velocity between the TC group and the EC-nicotine free groups.</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tPA between the TC, EC-nicotine free and EC-nicotine groups</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Augmentation Index@75bpm between the TC group,EC-nicotine and the EC-nicotine free groups</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>tobacco cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: tobacco cigarettes min 15/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>e.cigarettes + 16mg nicotine &amp; flavor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: One flavoured electronic cigarette 16mg nicotine/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>e.cigarettes + 0mg nicotine &amp; flavour</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: One electronic cigarette with flavour +0mg nicotine/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>electronic cigarette + 16mg nicotine &amp; flavor</intervention_name>
    <description>comparison of different strengths of nicotine</description>
    <arm_group_label>e.cigarettes + 16mg nicotine &amp; flavor</arm_group_label>
    <other_name>vapourlites</other_name>
    <other_name>e.cigarette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electronic cigarette + 0mg nicotine &amp; flavor</intervention_name>
    <description>comparison of different strengths of nicotine</description>
    <arm_group_label>e.cigarettes + 0mg nicotine &amp; flavour</arm_group_label>
    <other_name>vapourlites</other_name>
    <other_name>e.cigarette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tobacco cigarette</intervention_name>
    <description>Participant to remain on traditional cigarettes for 28 days</description>
    <arm_group_label>tobacco cigarette</arm_group_label>
    <other_name>Traditional cigarette, any brand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years and over

          -  Currently smoking â‰¥15 full strength tobacco cigarettes per day for at least 2 years,
             or roll-up tobacco equivalent (cigar or pipe smokers not included).

          -  Willing to stop tobacco cigarettes for period of study if required

          -  Willing not to use electronic cigarettes if required

          -  Able to give informed consent

        Exclusion Criteria:

          -  Pregnant or lactating.

          -  Women of childbearing potential who do not abstain from sex or use effective
             contraception.

          -  On current prescribed medication for cardiovascular disease.

          -  History of cardiovascular disease (excluding hypertension), diabetes, active
             malignance or chronic renal disease.

          -  Nut allergy

          -  Participation in another clinical trial (other than observational trials and
             registries) with an investigational product and/or intervention within 30 days before
             visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob George</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Dundee</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>February 2, 2019</last_update_submitted>
  <last_update_submitted_qc>February 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Professor. Jacob George</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02878421/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02878421/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

